Fake Rabies Vaccines Seized in Delhi: DCGI Issues Nationwide Alert Over Sub-Standard and Counterfeit Abhayrab Batches
_1294696147.jpg)
Public health safety has faced a shocking breach following the discovery of suspected counterfeit and sub-standard anti-rabies vaccines circulating in the market. The Drugs Controller General of India (DCGI) has issued an urgent nationwide alert after a specific batch of Abhayrab—a widely used vaccine administered for the prevention of rabies following animal bites—failed critical potency tests at a government laboratory. The alarming investigation came to light after enforcement authorities recovered suspicious vials from an unlicensed premises in Mukherjee Nagar, Delhi, triggering immediate concern among medical professionals and patients alike given that thousands of lives depend on effective rabies treatment across the country.
Investigation Uncovers 17 Discrepancies as Manufacturer Denies Production
The core of the investigation centers around batch number KE25012 of the Abhayrab vaccine. Following the seizure in New Delhi, samples were sent to the Central Drugs Laboratory in Kasauli, where tests confirmed the vaccine failed to meet mandatory potency requirements, leading to its formal classification as Not of Standard Quality. Indian Immunologicals Limited (IIL), the legitimate manufacturer of Abhayrab, issued a definitive clarification stating that the seized vials were never produced by the company. Upon comparing the recovered stock with authentic manufacturing records, authorities and company officials identified a staggering 17 distinct discrepancies in the packaging, labeling, QR codes, cap colors, and licensing information, confirming that counterfeiters had illicitly duplicated the brand name.
Authorities Crack Down on Illicit Ring as Delhi Police Make Arrests
Swift action by law enforcement has led the Delhi Police to apprehend four individuals linked to the distribution of the fake vaccines, while central and state drug controllers trace the supply chain to uncover where the spurious vials originated and how far they penetrated the market. The Central Drugs Standard Control Organization (CDSCO) has directed all state drug controllers to maintain rigorous surveillance over the sale and distribution of batch KE25012. Meanwhile, Indian Immunologicals Limited has assured the public that authentic supplies distributed through its verified channels remain completely safe, noting that the genuine production run of batch KE25012 comprised 83,370 authorized vials subjected to rigorous pre-market government testing.
Recurring Counterfeit Threats and the Vital Importance of Rabies Defense
This disturbing incident marks the second time in two years that counterfeit Abhayrab stock has triggered regulatory alarms, following a similar detection involving batch KA24014 in January 2025 that drew international travel alerts from health authorities in the US, UK, and Australia. With public health data indicating that approximately 5,726 people die from rabies annually in India, access to genuine, potent immunizations following animal bites is a matter of life and death. Authorities urge healthcare providers and patients to carefully verify vaccine packaging through authorized distribution networks to ensure complete safety and efficacy.
_8357189_351x234.jpg)
_1107133478_351x234.jpg)
_1038740737_351x234.jpg)
_1715200495_351x234.jpg)
_935290616_351x234.jpg)
